INSERM U886, CIC de Lyon, Hospices Civils de Lyon, Université Claude Bernard Lyon, Lyon, France.
Antioxid Redox Signal. 2011 Mar 1;14(5):811-20. doi: 10.1089/ars.2010.3354. Epub 2010 Oct 6.
Reperfusion therapy is the indispensable treatment of acute myocardial infarction (AMI) and must be applied as soon as possible to attenuate the ischemic insult. Evidence indicates that reperfusion is responsible for additional myocardial damage likely involving opening of the mitochondrial permeability transition pore. Ischemic postconditioning is a new way to dramatically reduce the lethal reperfusion injury. Several clinical studies using angioplasty postconditioning now support its protective effects in patients with an AMI. An interesting alternative is pharmacological postconditioning, which could be applied to a much larger number of patients. The mitochondrial permeability transition pore inhibitor cyclosporine A has been shown to generate a comparable protection in AMI patients. Future large-scale trials are needed to determine whether postconditioning may improve clinical outcome in ST-segment elevation MI patients.
再灌注治疗是急性心肌梗死(AMI)不可或缺的治疗方法,必须尽快应用以减轻缺血损伤。有证据表明,再灌注导致了可能涉及线粒体通透性转换孔开放的额外心肌损伤。缺血后处理是一种显著减少致命性再灌注损伤的新方法。目前,几项采用血管成形术后处理的临床研究支持其对 AMI 患者的保护作用。一种有趣的替代方法是药物后处理,它可以应用于更多的患者。已经证明,线粒体通透性转换孔抑制剂环孢素 A 可在 AMI 患者中产生类似的保护作用。需要进行大规模的未来试验来确定后处理是否可以改善 ST 段抬高型心肌梗死患者的临床结局。